ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 120

Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease

Geoffrey Gillard1, Jennifer Proctor 1, Melissa Brooks 1, Tahirih Lamothe 1, Sharon Hyzy 1, Sean McDonough 1, Rahul Palchaudhuri 2, Anjali Bhat 1, Ganapathy Sarma 1, Prashant Bhattarai 1, Pranoti Sawant 1, Brad Pearse 1, Charlotte McDonagh 1, Anthony Boitano 1 and Michael Cooke 1, 1Magenta Therapeutics, Cambridge, MA, 2Magenta Therapeutics, Cambridge

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, immune tolerance and autologous transplantation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in selected patients with autoimmune diseases. AutoHSCT can induce long-term remission (up to 15 years) with 70-80% progression free survival in patients with relapsed refractory and secondary progressive multiple sclerosis (Muraro 2017) that is superior to standard of care agents in a randomized study (Burt 2019).  Likewise, use of autoHSCT in patients with scleroderma achieved superior outcomes in two randomized studies (Tyndall 2014, Sullivan 2018).  These impressive results are achieved by eradication of autoreactive immune cells and re-establishment of a self-tolerant immune system, i.e., immune system reset.  However, only a small fraction of eligible patients undergo autoHSCT, in part due to toxicity associated with current conditioning protocols. To address these issues, we are developing antibody drug conjugates (ADCs) that selectively target CD45 to eradicate autoimmune cells and enable autoHSCT as a potentially one-time curative treatment for patients with autoimmune disease.

Methods: We generated a novel ADC targeting murine CD45 that was evaluated as a single conditioning agent for murine congenic transplant.  This ADC was further evaluated for its ability to eliminate pathogenic host-reactive cells in the context of multiple murine models of autoimmune disease, including MOG-induced experimental autoimmune encephalitis (EAE), proteoglycan-induced arthritis (PGIA), and sclerodermatous graft-vs-host disease (scGVHD). To translate these encouraging pre-clinical data we generated novel anti-human CD45 ADCs that cross react with nonhuman primates (NHP) and evaluated these for the ability to deplete hematopoietic and immune cells in NHPs.

Results: A single-dose of anti-mouse CD45-ADC achieved full myeloablation in recipient mice and enabled full donor chimerism in a congenic mouse transplant model. In EAE, conditioning with anti-mouse CD45-ADC followed by congenic transplant prior to disease onset significantly delayed disease onset and reduced overall disease severity. In active EAE, treatment with anti-mouse CD45-ADC followed by congenic transplant halted progression of disease activity. The disease modifying effect in EAE with anti-mouse CD45-ADC showed comparable efficacy to a traditional conditioning regimen.  Evaluation of CD45-ADC in additional autoimmune models of arthritis and scleroderma are ongoing and will be presented. Given these encouraging results we developed an anti-human CD45 ADC that cross-reacts with non-human primates (NHP).  Substantial depletion of both lymphocytes and hematopoietic stem cells (HSCs) was observed at well-tolerated doses.

Conclusion: These results suggest that targeted immune depletion with a single treatment of CD45-ADC may be sufficient for auto-HSCT and allow re-establishment of immune tolerance.  Targeted CD45-ADCs may represent a safer and better tolerated approach for conditioning patients prior to immune reset through autoHSCT and significantly reduce the side effects associated with current conditioning.

Administration of CD45-ADC enables autoHSCT and substantially reduces pathology in murine EAE model


Disclosure: G. Gillard, Magenta Therapeutics, 1, 3, 4; J. Proctor, Magenta Therapeutics, 1, 3, 4; M. Brooks, Magenta Therapeutics, 1, 3, 4; T. Lamothe, Magenta Therapeutics, 1, 3, 4; S. Hyzy, Magenta Therapeutics, 1, 3, 4; S. McDonough, Magenta Therapeutics, 1, 3, 4; R. Palchaudhuri, Magenta Therapeutics, 1, 3, 4; A. Bhat, Magenta Therapeutics, 1, 3, 4; G. Sarma, Magenta Therapeutics, 1, 3, 4; P. Bhattarai, Magenta Therapeutics, 1, 3, 4; P. Sawant, Magenta Therapeutics, 1, 3, 4; B. Pearse, Magenta Therapeutics, 1, 3, 4; C. McDonagh, Magenta Therapeutics, 1, 3, 4; A. Boitano, Magenta Therapeutics, 1, 2, 4; M. Cooke, Magenta Therapeutics, 1, 3, 4.

To cite this abstract in AMA style:

Gillard G, Proctor J, Brooks M, Lamothe T, Hyzy S, McDonough S, Palchaudhuri R, Bhat A, Sarma G, Bhattarai P, Sawant P, Pearse B, McDonagh C, Boitano A, Cooke M. Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/administration-of-a-cd45-antibody-drug-conjugate-as-a-novel-targeted-approach-to-achieve-immune-system-reset-a-single-dose-of-cd45-targeted-adc-safely-conditions-for-autologous-transplant-and-amelio/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/administration-of-a-cd45-antibody-drug-conjugate-as-a-novel-targeted-approach-to-achieve-immune-system-reset-a-single-dose-of-cd45-targeted-adc-safely-conditions-for-autologous-transplant-and-amelio/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology